Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment
European Journal of Neurology · 2024-04 · 31 (4)
DOI: 10.1111/ene.16206 ↗At a glance
Journal article in European Journal of Neurology, published online on 2024-01-25. Written by Richard Smith and 9 co-authors. Institution: Center for Neurologic Study, La Jolla, California, USA. Major MEDLINE topics: alpha-Synuclein, Amyotrophic Lateral Sclerosis. Cited 19 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Alpha‐synuclein (α‐Syn) oligomers and fibrils have been shown to augment the aggregation of TAR DNA‐binding Protein 43 (TDP‐43) monomers in vitro, supporting the idea that TDP‐43 proteinopathies such as ALS may be modulated by the presence of toxic forms of α‐Syn. Recently, parkinsonian features were reported in a study of European patients and Lewy bodies have been demonstrated pathologically in a similar series of patients. Based on these and other considerations, we sought to determine whether seed‐competent α‐Syn can be identified in spinal fluid of patients with ALS including familial, sporadic, and Guamanian forms of the disease.
Methods
Based on the finding that α‐Syn has been found to be a prion‐like protein, we have utilized a validated α‐Synuclein seed amplification assay to determine if seed‐competent α‐Syn could be detected in the spinal fluid of patients with ALS.
Results
Toxic species of α‐Syn were detected in CSF in 18 of 127 ALS patients, 5 of whom were from Guam. Two out of twenty six samples from patients with C9orf72 variant ALS had positive seed‐amplification assays (SAAs). No positive tests were noted in superoxide dismutase type 1 ALS subjects ( n = 14). The SAA was negative in 31 control subjects.
Conclusions
Our findings suggest that a sub‐group of ALS occurs in which self‐replicating α‐Syn is detectable and likely contributes to its pathogenesis. This finding may have implications for the diagnosis and treatment of this disorder.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Neurologic Study, La Jolla, California, USA.
- Amprion Clinical Laboratory, San Diego, California, USA.
- Barrow Neurological Institute, Phoenix, Arizona, USA.
- Binghamton University, Binghamton, New York, USA.
- University of Ulm, Ulm, Germany.
- University of California, San Diego, La Jolla, California, USA.
ORCID profiles: Richard Smith
Cite
APA
Smith, R., Hovren, H., Bowser, R., Bakkar, N., Garruto, R., Ludolph, A., Ravits, J., Gaertner, L., Murphy, D., & Lebovitz, R. (2024). Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment. European Journal of Neurology, 31(4). https://doi.org/10.1111/ene.16206
Vancouver
Smith R, Hovren H, Bowser R, Bakkar N, Garruto R, Ludolph A, et al. Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment. European Journal of Neurology. 2024;31(4). doi:10.1111/ene.16206
BibTeX
@article{Smith2024,
author = {Smith, Richard and Hovren, Hanna and Bowser, Robert and Bakkar, Nadine and Garruto, Ralph and Ludolph, Albert and Ravits, John and Gaertner, Lia and Murphy, Davan and Lebovitz, Russ},
title = {Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {4},
doi = {10.1111/ene.16206}
}
EUVIMED